Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre RCT phase III thelancet.com/journals/lanon…
Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response? Co-authored by @fdossa.
Read the full article. bit.ly/4vuPmU8
I was skeptical of virtual twin studies but @fdossa convinced me they have a role, especially for our patients with rare cancer. Look forward to seeing what’s next out of this line of research #ASCO26#sarcoma 👇🏻
SARC041: confirms clinical activity of abemaciclib for pts with advanced dediff liposarcoma ✅
👏🏽 to Mark Dickson @MSKSarcoma on this work and Paolo Casali @casali_pg@IstTumori for an excellent discussion
Open❔role in resectable disease
#ASCO26
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM@ASCO
This is a great read on watch & wait in rectal cancer.
B/c patients with local regrowth after WW have higher rates of distant mets, there has been an intuitive fear that regrowth is causal (i.e delaying TME permits metastatic seeding hence WW risky).
The authors here argue (and I agree) that regrowth/metastases are manifestations of intrinsic aggressive tumor biology because:
1) no difference in time to surgery in patients w pCR/regrowth who developed mets vs. those who didn't (if delay were causal, would expect longer delay in patients who developed M1).
2) in OPRA secondary analysis, patients with cCR underwent least surgery/longest observation while those with incomplete response had surgery most frequently/immediately. But outcomes still tracked with response phenotype not timing of surgery (i.e. cCR did best).
3) tumor response itself is prognostic (i.e. even when all pts undergo TME, more regression after neoadjuvant therapy --> better DFS/DM).
4) modern tumor evolution data suggest metastatic spread mostly happens early.
5) chemo/radioresistance appears to be linked to metastatic potential (i.e. regrowth is a marker of aggressive biology not the mechanism itself).
IMO a persuasive argument against hypothesis that regrowth seeds metastasis, but rather biology=dominant driver. @OncoAlert
Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response? | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
With ⤴️use of W&W for rectal cancer, how can we safely 🫸the limits? Is there a role for W&W in pts with *near* complete response or does this risk distant disease?
More on the📊 and our recommendations for safe W&W practices: ascopubs.org/doi/10.1200/JCO…@JCO_ASCO @DrGarciaAguilar
Celebrating @seacm on receiving the AHPBA Research Development Grant. This is the impact we strive for: advancing science, elevating care and leading the way.
uab.edu/medicine/news/surger…